NVO 全部观点

已加载 5 条观点条目,其中 0 条方向发生变化

在已加载记录中筛选
The Investor's Podcast发布 2026-10-31
《S&P Global (SPGI), Novo Nordisk (NVO), Deckers (DECK) | Stock Analysis & Valuation (TIP857)》
$NVO看涨
AI 摘要 · 看多 NVO:其前瞻市盈率约 12 倍——仅为标普 20 多倍市盈率的一半,而礼来为 24 倍——大部分坏消息已被计入。基准情形为中个位数盈利增长加上 4.5% 股息率,五年内年化回报 8–9%(含股息最高 10%);若口服减肥药和处于三期的 amiritin 在 2028 年前成功,重估后回报可达 18–22%。他不指望明年翻倍,并提到 Medicare 定价、专利到期/仿制药、指引下调至 2030 年以及价值陷阱/创新风险。

所以我今天的选择是两年前欧洲市值最高的公司之一。几乎人人都持有它。我不知道你Stig是否持有,但很多人、很多ETF、很多基金都持有这家公司。

So my pick today is one of those companies which two years ago was the most valuable company in Europe. And pretty much everybody owned it. I don't know whether you owned it Stig, but pretty much a lot of people, a lot of ETFs, a lot of funds owned this company.

分析师非常喜欢它。但今天这只股票下跌了40%。从52周高点算起,而且它的交易价格大约是远期盈利的12倍,基本上所有人都在说派对结束了。

The analysts really loved it. But today that stock is down 40%. And from its 52- week high and it's trading roughly around 12 times forward earnings and basically everybody's saying parties over here.

他说在等
amiritin三期试验成功及上市
到2028年取得成功的三期试验结果/上市
到2028年amiritin三期试验结果
支撑18-22%回报/上行空间的情形
Parkev Tatevosian, CFA发布 2026-09-26
《Novo Nordisk Gives Uninspiring Outlook》
$NVO看涨
AI 摘要 · 尽管估值与信心有所下调,NVO 仍值得买入,仍有显著上行空间。

诺和诺德向投资者表示,到2030年公司将实现中个位数的收入增长。公司还表示,将把所服务的患者人数从目前的约4650万提升至6000万以上。

Novo Nordisk informed investors that it will increase its revenue at a medium single-digit rate through 2030. It also stated that it will increase the number of patients it serves to more than 60 million, up from about 46.5 million currently.

尽管预期强劲,投资者对诺和诺德的表现并不买账。自2026年初以来,该股已下跌超过25%。那么,这一切是否让诺和诺德在股价下跌时成为一个买入机会?

Despite these strong expectations, investors were not impressed with Novo Nordisk's performance. The stock has fallen by more than 25% since the beginning of 2026. So, does all this make Novo a buying opportunity when its price drops?

Schwab Network发布 2026-09-21
《Iran & China at Forefront of Trading Week, Critical Metals Rally & NVO Slides》
$NVO看跌
AI 摘要 · NVO股价承压,因市场认为其战略计划不够大胆或推进不够快,不过40美元处存在技术支撑。

现在来谈谈Novo,也就是此前的Novo Nordisk。该公司股价今早承压。市场似乎对Novo公布的下一阶段战略计划感到不满。

Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.

显然,他们的减肥药曾需求旺盛,至少在初期阶段是如此。但如今,竞争已经进入这一领域,并抢走了他们的部分市场份额。

It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.

Schwab Network发布 2026-09-11
《Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade》引用来源:Morgan Stanley
$NVO看跌
AI 摘要 · Morgan Stanley 将 NVO 下调至减持评级,40 美元目标价意味着较当前水平存在下行空间,原因是增长担忧与专利悬崖风险。

好。最后但同样重要的是,我们来看Novo Nordisk。我看到了一次下调评级,以及一个低于当前股价的目标价。

All right. And last but not least, we look at Novo Nordisk. I saw a downgrade and a price target below where we are now.

已经是最早的记录
其他股票的全部观点条目
把 $NVO 加入我的股票30 天完整试用
开始试用